Malate, a natural inhibitor of 6PGD, improves the efficacy of chemotherapy in lung cancer
- 25 March 2024
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 190, 107541
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Tianjin Science and Technology Correspondent Project
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
This publication has 51 references indexed in Scilit:
- PRMT6 promotes tumorigenicity and cisplatin response of lung cancer through triggering 6PGD/ENO1 mediated cell metabolismActa Pharmaceutica Sinica B, 2022
- Targeting G6PD reverses paclitaxel resistance in ovarian cancer by suppressing GSTP1Biochemical Pharmacology, 2020
- 6‐Phosphogluconate dehydrogenase fuels multiple aspects of cancer cells: From cancer initiation to metastasis and chemoresistanceBioFactors, 2020
- Malic acid production from renewables: a reviewJournal of Chemical Technology & Biotechnology, 2019
- Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detectionBiomedicine & Pharmacotherapy, 2017
- PKM1 is involved in resistance to anti-cancer drugsBiochemical and Biophysical Research Communications, 2016
- Sunitinib Malate2012
- Kinase Inhibitor Selectivity Profiling Using Differential Scanning Fluorimetry2011
- Malate dehydrogenase: A model for structure, evolution, and catalysisProtein Science, 1994
- Inhibition of 6-phosphogluconate dehydrogenase by glucose 1,6-diphosphate in human normal and malignant colon extractsCancer Letters, 1984